Cipher Pharma has a huge upside, says Echelon Wealth

Mar 21 20:03 2019 Print This Article

Look for Cipher Pharmaceuticals (Cipher Pharmaceuticals Stock Quote, Chart TSX:CPH) to break out of its slump in 2019, says Doug Loe of Echelon Wealth Partners. Loe gives a 12-month return of 257 per cent for the stock, saying the specialty pharma company’s pipeline prospects are encouraging. Cipher Pharmaceuticals released its fourth quarter and fiscal 2018 […]

The post Cipher Pharma has a huge upside, says Echelon Wealth appeared first on Cantech Letter.

Read More

About Article Author

Cantech Letter

Founded in 2008 by Nick Waddell, Cantech Letter is an online magazine focusing on Canadian technology. The site has grown into one of the most popular and respected financial sites in Canada, and was described by Canadian Business Magazine as “one of Canada’s premier technology newsletters”. Waddell, who is Senior Editor, is routinely called on by the mainstream media for perspective on Canadian technology, and has been featured on BNN, CTV News Channel, and the CBC program “The Lang and O’Leary Exchange” in addition to mainstream print media such as The Guardian, The International Business Times, The Globe and Mail, Macleans, The Waterloo Record , Canadian Business, Slate, and Business Insider. You can email Nick at nick@cantechletter.com Cantech Letter is focused on those companies listed on the TSX and TSXV Technology, Cleantech and Life Sciences Sectors. Each year we present the Cantech Letter Awards, which honor Canada’s Top Technology Stock and Top Technology Stock Executive.

Related Items

Ottawa postpones short-sighted drug-pricing regulations

Author: Bacchus Barua Planned changes would likely result in fewer new and innovative drugs available to Canadians. Read more about Ottawa postpones short-sighted drug-pricing regulations Tags:  pmprb pharmaceutical drugs pharmaceutical innovation prescription drug prices ...

Customer Success: Formulary Management

In response to customer requests, we’ve built some new tools for formulary management. You can preview these tools at: Recent Generic Drug Launches Upcoming 180-Day Patent Challenge Exclusivity Expirations Anticipate… The post Customer Success: Formulary Management appeared first on DrugPatentW ...

There’s still upside to Aurinia Pharma, says Mackie Research

All eyes are on a 2021 launch of voclosporin, lead candidate from drug developer Aurinia Pharmaceuticals (Aurinia Pharma Stock Quote, Chart, News NASDAQ:AUPH), but the stock received a target price trim from analyst André Uddin of Mackie Research on Friday, going from $24.00 to $22.00 per share. V ...

GW Pharmaceuticals is a world leader, AltaCorp Capital says

As the world’s first company to commercialize a plant-based cannabinoid-derived pharmaceutical, GW Pharmaceuticals (GW Pharmaceuticals Stock Quote, Chart, News NASDAQ:GWPH) stands out as a Top Pick for 2020, according to David M. Kideckel, analyst for AltaCorp Capital, who stayed bullish on the n ...

Q4 2019 Share Price Performance

Q4 2019 Share Price Performance Healthcare Stocks Surge  In this blog post, the Bloom Burton equity research team summarizes the performance of the Canadian healthcare sector during 4Q-2019, and provides commentary on select stock movements and overall market trends.  Inclusion Criteria  Our ana ...

MedX Health has tons of upside, says Beacon Securities

Beacon Securities analyst Doug Cooper thinks the market has so far ignored a series of recent game-changing announcements by medical technology company MedX Health (MedX Health Stock Quote, Chart, News TSXV:MDX). That scenario, said Cooper in a June 16 update to clients, makes for a prime investmen ...

Profound Medical is insulated from COVID-19, says Raymond James

Looking for bright spots within the ongoing market deluge? Raymond James analyst Rahul Sarugaser says Profound Medical (Profound Medical Stock Quote, Chart, News TSX:PRN) should be top of mind, as the company appears to be well-insulated with respect to the COVID-19 pandemic. In an update to client ...

CRH Medical has price target cut at Beacon Securities

CRH Medical Corporation (CRH Medical Corporation Stock Quote, Chart, News TSX:CRH) hung onto its “Buy” rating from Beacon Securities analyst Doug Cooper after disappointing fourth quarter results. The analyst reviewed the Q4 in an update to clients on Thursday and reduced his target by half. Va ...

Oncolytics Biotech is “dramatically undervalued”, says Echelon Wealth

Alberta-based biologics developer Oncolytics Biotech (Oncolytics Biotech Stock Quote, Chart, News TSX:ONC) has a clear roster of clinical milestones ahead for its flagship virus formulation, according to Echelon Wealth Partners analyst Doug Loe, who reviewed the company’s quarterly results and ge ...